-
公开(公告)号：US10080741B2
公开(公告)日：2018-09-25
申请号：US15497268
申请日：2017-04-26
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Yat Sun Or , Brett Granger , Ruichao Shen , Xuechao Xing , Bin Wang , Jun Ma , Jing He , Jiang Long , Yong He , Guoqiang Wang
IPC: C07D261/08 , C07D413/12 , A61K31/42 , C07D261/06 , C07D413/04
CPC classification number: A61K31/42 , C07D261/06 , C07D261/08 , C07D413/04 , C07D413/12
Abstract: The present invention provides compounds of Formula I: pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.
-
公开(公告)号：US20170304271A1
公开(公告)日：2017-10-26
申请号：US15497307
申请日：2017-04-26
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Yat Sun Or , Ruichao Shen , Xuechao Xing , Brett Granger , Bin Wang , Jun Ma , Jing He , Yong He , Jiang Long , Guoqiang Wang
IPC: A61K31/42 , C07D277/62 , C07D275/04 , C07D261/08 , A61K31/64 , A61K31/545 , A61K31/4725 , C07D413/12 , A61K31/426
CPC classification number: A61K31/42 , A61K31/426 , A61K31/4725 , A61K31/545 , A61K31/64 , C07D261/08 , C07D275/04 , C07D277/62 , C07D413/12 , C07D413/14 , C07D417/14
Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.
-
公开(公告)号：US20170240585A1
公开(公告)日：2017-08-24
申请号：US15439358
申请日：2017-02-22
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Guoqiang Wang , Yat Sun Or , Jiang Long , Guoyou Xu , Peng Dai , Ruichao Shen , Xuechao Xing , Jing He
CPC classification number: C07J41/0055 , C07B59/007 , C07B2200/05 , C07J9/005 , C07J17/00 , C07J43/003 , C07J51/00
Abstract: The present invention provides compounds of Formula (I) or Formula (II): pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR and/or TGR5.
-
公开(公告)号：US09493506B2
公开(公告)日：2016-11-15
申请号：US14299095
申请日：2014-06-09
Applicant: Enanta Pharmaceuticals, Inc. , AbbVie, Inc.
Inventor： Hui-Ju Chen , Keith F. McDaniel , Brian E. Green , Jason P. Shanley , Albert W. Kruger , Jorge Gandarilla , Dennie S. Welch , Russell D. Cink , Steven C. Cullen , Yonghua Gai , Guoqiang Wang , Yat Sun Or
IPC: C07D487/04 , C07K5/083
CPC classification number: C07K5/081 , C07D487/04
Abstract: The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.
-
公开(公告)号：US09220748B2
公开(公告)日：2015-12-29
申请号：US14146161
申请日：2014-01-02
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Yat Sun Or , Jun Ma , Guoqiang Wang , Jiang Long , Bin Wang
CPC classification number: C07K5/123 , A61K38/00 , A61K38/12 , A61K45/06 , C07K5/06034 , C07K5/0808 , C07K5/0823 , C07K5/0827 , C07K14/811
Abstract: The present invention discloses compounds of Formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Abstract translation: 本发明公开了式I化合物或其药学上可接受的盐，酯或前药：其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
-
Patent Agency Ranking
86.发明授权公开(公告)号：US09156886B2
公开(公告)日：2015-10-13
申请号：US13734074
申请日：2013-01-04
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Yat Sun Or , Guoqiang Wang , Jiang Long , Xuri Gao
IPC: A61K38/13 , A01N37/18 , A61K38/00 , A61P31/12 , A61K31/18 , C07K7/52 , A61K31/7088 , A61K38/21 , A61K45/00
CPC classification number: A61K38/13 , A61K31/7088 , A61K38/21 , A61K45/00 , A61K45/06 , C07K7/52 , C07K7/645 , Y02A50/463
Abstract: The present invention relates to cyclosporin analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporin analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.
Abstract translation: 本发明涉及对HCV具有抗病毒活性的环孢菌素类似物，可用于治疗HCV感染。 更具体地，本发明涉及新的环孢菌素类似物化合物，含有这些化合物的组合物及其使用方法，以及制备这些化合物的方法。
-
![[N-Me-4-hydroxyleucine]-9-cyclosporin analogues for treatment and prevention of hepatitis C infection](/abs-image/US/2014/12/09/US08906853B2/abs.jpg.150x150.jpg)
87.发明授权[N-Me-4-hydroxyleucine]-9-cyclosporin analogues for treatment and prevention of hepatitis C infection 有权[N-Me-4-羟基亮氨酸] -9-环孢菌素类似物用于治疗和预防丙型肝炎感染公开(公告)号：US08906853B2
公开(公告)日：2014-12-09
申请号：US14092171
申请日：2013-11-27
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Yat Sun Or , In Jong Kim , Jiang Long , Lijuan Jiang , Sheng Sean Liu , Guoqiang Wang
IPC: A61K38/21 , A61K31/7056 , A61K45/06 , C07K7/64 , A61K31/713
CPC classification number: C07K7/645 , A61K31/7056 , A61K31/713 , A61K38/21 , A61K45/06 , C07K7/64 , Y02A50/463 , A61K2300/00 , A61K38/13
Abstract: The present invention relates to novel cyclosporine analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporine analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.
Abstract translation: 本发明涉及对HCV具有抗病毒活性的新型环孢菌素类似物，可用于治疗HCV感染。 更具体地，本发明涉及新的环孢菌素类似物化合物，含有这些化合物的组合物及其使用方法，以及制备这些化合物的方法。
-
公开(公告)号：US20140187780A1
公开(公告)日：2014-07-03
申请号：US14139936
申请日：2013-12-24
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： In Jong Kim , Tongzhu Liu , Jiang Long , Guoqiang Wang , Yao-Ling Qiu , Heejin Kim , Yanchun Wang , Ly Tam Phan , Yat Sun Or
IPC: C07D493/08 , C07F9/6558
CPC classification number: C07D493/08 , C07F9/65586 , C07H17/08
Abstract: The present invention discloses compounds of formula I, II or X, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.
Abstract translation: 本发明公开了式I，II或X的化合物或其药学上可接受的盐，酯或前药：其表现出抗菌性质。 本发明还涉及包含上述化合物的药物组合物，用于给予需要抗生素治疗的受试者。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的细菌感染的方法。 本发明还包括制备本发明化合物的方法。
-
公开(公告)号：US20130315864A1
公开(公告)日：2013-11-28
申请号：US13897023
申请日：2013-05-17
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Yat Sun Or , Jun Ma , Guoqiang Wang
IPC: C07H19/207 , A61K31/7064 , C07H19/10 , A61K31/7076 , A61K45/06
CPC classification number: C07H19/207 , A61K31/7064 , A61K31/7076 , A61K45/06 , C07H19/10 , C07H19/14 , C07H19/20 , C07H19/23 , A61K2300/00
Abstract: The present invention provides nucleoside phosphoramidate compounds of Formula I, where R1, R2a, R2b, R3, R4, R5a, R5b, R6, R7, R8a, R8b, M and W are as defined herein. The invention further includes pharmaceutical compositions comprising a compound of Formula I, methods of use of these compounds for treating a viral infection, and methods of producing these compounds.
Abstract translation: 本发明提供式I的核苷氨基磷酸酯化合物，其中R1，R2a，R2b，R3，R4，R5a，R5b，R6，R7，R8a，R8b，M和W如本文所定义。 本发明还包括含有式I化合物的药物组合物，这些化合物用于治疗病毒感染的方法，以及制备这些化合物的方法。
-
公开(公告)号：US11858945B2
公开(公告)日：2024-01-02
申请号：US17983484
申请日：2022-11-09
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Joseph D. Panarese , Samuel Bartlett , Guoqiang Wang , Yat Sun Or
IPC: C07D487/10 , C07D519/00
CPC classification number: C07D487/10 , C07D519/00
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof:
which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
-
-
-
-
-
-
-
-
-
Search Results
154
records
(took 0.045 seconds)
